Page last updated: 2024-08-24

tenofovir and jtk-303

tenofovir has been researched along with jtk-303 in 95 studies

Research

Studies (95)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (1.05)	29.6817
2010's	72 (75.79)	24.3611
2020's	22 (23.16)	2.80

Authors

Authors	Studies
Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M	1
Cheng, A; Kearney, BP; Ramanathan, S; Shen, G	1
German, P; Hui, J; Kearney, BP; Warren, D; West, S	1
Engelman, A; Haim, H; Koh, Y	1
Chuck, SL; Cohen, C; DeJesus, E; Elion, R; Kearney, BP; Liu, HC; Ramanathan, S; Rashbaum, B; Ruane, P; Shamblaw, D; Warren, DR; Yale, K	1
Cheng, AK; DeJesus, E; Gathe, J; Henry, K; Kearney, BP; Molina, JM; Ramanathan, S; Rockstroh, JK; Szwarcberg, J; Wei, X; White, K; Yale, K	1
Cheng, AK; Cohen, C; DeJesus, E; Gallant, JE; Kearney, BP; Liu, HC; Mills, A; Quirk, E; Sax, PE; Szwarcberg, J; White, K; Wohl, D; Yale, K; Zhong, L; Zolopa, A	1
Debyser, Z; Schrijvers, R	2
Pommer, P	1
Andreatta, K; Miller, MD; White, KL	1
Belavic, JM	1
Abram, M; Cheng, AK; DeJesus, E; Fordyce, MW; Gathe, J; Henry, K; Molina, JM; Plummer, A; Ramanathan, S; Rockstroh, JK; Szwarcberg, J; Wei, X	1
Binet, L; Djerada, Z; Feliu, C; Gozalo, C; Lamiable, D; Marty, H; Millart, H; Robinet, A; Tournois, C; Vautier, D	1
Aldir, I; Horta, A; Serrado, M	1
Ikeda, A; Irie, S; Ishikawa, T; Kimura, M; Matsuki, S; Nishino, N; Shiomi, M	1
Hsiao, CB; Ma, Q; Sawyer, JR	1
Ayala-Sims, VA; Fulco, PP	1
Antela, A; Domingo, P; Garner, W; Girard, PM; Guyer, B; Henry, K; Markowitz, M; Mills, A; Nguyen, T; Piontkowsky, D; Pozniak, A; Stellbrink, HJ; White, K	1
Arribas, JR; Di Perri, G; Ebrahimi, R; Gathe, J; Nguyen, T; Pialoux, G; Piontkowsky, D; Reynes, J; Tebas, P; White, K	1
Hluhanich, R; Kulkarni, R; McColl, DM; Miller, MD; White, KL	1
Cheng, AK; Kulkarni, R; McColl, DJ; Miller, MD; Rhee, MS; Szwarcberg, J; White, KL	1
Abram, ME; Andrade-Villanueva, JF; Beraud, C; Cheng, AK; Fisher, M; Graham, H; Liu, Y; Post, FA; Rhee, MS; Szwarcberg, J; Winston, J	1
Baeten, JM; Wyatt, C	1
Andrade-Villanueva, J; Callebaut, C; Cao, H; Cheng, AK; Crofoot, G; Custodio, JM; DeJesus, E; Fordyce, MW; Koenig, E; Martin, H; McCallister, S; Molina, JM; Oka, S; Plummer, A; Podzamczer, D; Post, F; Pozniak, A; Saag, M; Sax, PE; Thompson, M; Trottier, B; Wohl, D; Yin, MT; Zhong, L	1
Bender, R; Berenguer, J; Garner, W; Mills, A; Nguyen, T; Pozniak, A; Speck, RM	1
Andreatta, KN; Miller, MD; White, KL	1
Abram, ME; Arribas, JR; Avihingsanon, A; Benson, P; Bloch, M; Cheng, A; Chetchotisakd, P; Crofoot, G; Custodio, JM; Fordyce, MW; Gathe, J; Gupta, SK; Lichtenstein, K; McCallister, S; Post, FA; Pozniak, A; Ramgopal, M; SenGupta, D; Wei, X	1
Bonora, S; Calcagno, A; Di Perri, G; Trentalange, A	1
Arribas, JR; Brinson, C; Brunetta, J; Callebaut, C; Cheng, A; Cheret, A; Clarke, A; Clumeck, N; Das, M; Fordyce, M; Mussini, C; Oka, S; Rashbaum, B; Sax, PE; Stephens, J; Tashima, K; Tebas, P; Wohl, D; Zhong, L	1
Callebaut, C; Fordyce, M; Kitrinos, KM; Margot, NA; McCallister, S; Miller, MD	1
Bertucci, R; Bonora, S; Calcagno, A; D'Avolio, A; Di Perri, G; Mornese Pinna, S; Motta, I; Simiele, M	1
Balogh, A; Iakoubov, R; Kern, KE; Noe, S; Schmid, RM; Schwerdtfeger, C; Spinner, CD; Von Werder, A; Wolf, E; Zink, A	1
Benson, P; Brinson, C; Brunetta, J; Cheng, A; Crofoot, G; Das, M; Fordyce, M; Gallant, J; Garner, W; McCallister, S; Mills, A; Oka, S	1
Deeks, ED; Greig, SL	1
Jones, R; Levy, JB; Milburn, J	1
Behrens, G; Borg, P; Bouee, S; M Llibre, J; Moyle, G; Piontkowsky, D; Raffi, F; Reilly, G; Rogatto, F	1
Destache, CJ; Mandal, S; Prathipati, PK	1
Avihingsanon, A; Cao, H; Cheng, A; Hagins, D; Hodder, S; Jiang, S; Johnson, M; Kityo, C; Koenig, E; Squires, K; Szwarcberg, J; Voronin, E; White, K	1
Batra, J; Chakraborty, R; Gaur, AH; Kizito, H; Kosalaraksa, P; Luesomboon, W; Myers, M; Porter, D; Prasitsueubsai, W; Quirk, E; Rakhmanina, N; Rassool, M; Rhee, MS; SenGupta, D; Shao, Y; Ting, L	1
Castagna, A; Chiappetta, S; Galli, L; Lazzarin, A; Nozza, S; Poli, A; Ripa, M; Rovelli, C; Spagnuolo, V; Tambussi, G	2
Imaz, A; Podzamczer, D	1
Destache, CJ; Fan, W; Kang, G; Li, Q; Mandal, S; Prathipati, PK; Yuan, Z; Zhou, Y	1
Ambrosioni, J; Miró, JM; Mosquera, MM	1
Blondel, L; Charpentier, C; Descamps, D; Joly, V; Landman, R; Lê, M; Matheron, S; Perrier, M; Peytavin, G; Pinto, A; Visseaux, B; Yazdanpanah, Y	1
Arribas, JR; Callebaut, C; Cheng, A; Clarke, AE; Das, M; DeJesus, E; Guo, S; Haas, B; McCallister, S; McDonald, C; Plummer, A; Sax, PE; Thompson, M; Wang, H; Wohl, DA	1
Ikushima, I; Irie, S; Ishikawa, T; Nemoto, T; Ninomiya, N; Yamada, H	1
Avettand-Fenoel, V; Bellecave, P; Bonnet, F; Caldato, S; Hessamfar, M; Morlat, P; Ngo Bell, EC; Saunier, A; Tumiotto, C; Vandenhende, MA	1
Bandera, A; Bonfanti, P; Calza, L; Carenzi, L; Celesia, BM; Cordier, L; De Socio, GV; Di Biagio, A; Falasca, K; Gori, A; Madeddu, G; Maggi, P; Martinelli, C; Orofino, G; Pellicanò, GF; Quirino, T; Ricci, E; Rusconi, S; Squillace, N; Vichi, F	1
Andreatta, K; Antinori, A; Berenguer, J; Bloch, M; Cote, P; Flamm, J; Garner, W; McColl, DJ; Nguyen-Cleary, T; Piontkowsky, D; Pozniak, A; Szwarcberg, J; Ward, D	1
Cao, H; Chang, S; Hodder, SL; Kulkarni, R; Miller, MD; White, KL	1
Baldelli, S; Cattaneo, D; Clementi, E; Galli, M; Gervasoni, C; Giacomelli, A; Mazzali, C; Meraviglia, P; Milazzo, L; Minisci, D; Resnati, C; Rizzardini, G	1
Shafer, RW	1
Arnaiz, JA; Cruceta, A; García, F; Gatell, JM; González, E; González-Cordón, A; Inciarte, A; Laguno, M; Leal, L; León, A; Lucero, C; Mallolas, J; Martínez-Rebollar, M; Rojas, J; Torres, B	1
Ganase, B; Harrigan, PR; Harris, M; Hull, MW; Montaner, JSG; Watson, B	1
DeJesus, E; Haas, B; Liu, YP; Makadzange, T; Margot, N; McCallister, S; Mills, A; Ramgopal, MN; Segal-Maurer, S	1
Avihingsanon, A; Cao, H; Cheng, A; Hagins, D; Hodder, S; Jiang, S; Kido, A; Kityo, C; Kulkarni, R; Squires, K	1
Álvarez, H; Díaz-Cambre, H; García-González, J; Llibre, JM; Mariño, A; Valcarce, N	1
Bagella, P; Baldin, G; Capetti, A; Ciccullo, A; Cossu, MV; De Luca, A; Di Giambenedetto, S; Giacomelli, A; Lagi, F; Latini, A; Madeddu, G; Rusconi, S; Sterrantino, G	1
Andreoni, M; Cerva, C; Maffongelli, G; Malagnino, V; Sarmati, L; Teti, E	1
Cottrell, ML; Garcia, B; Imaz, A; Kashuba, ADM; Morenilla, S; Niubó, J; Perez, E; Podzamczer, D; Tiraboschi, JM	1
Capetti, AF; Cossu, MV; Giacomet, V; Rizzardini, G; Zuccotti, G	1
Bickel, M; Cahn, P; Greaves, W; Hanna, GJ; Hwang, C; Johnson, M; Kumar, P; Kumar, S; Mallolas, J; Molina, JM; Morais, C; Rizzardini, G; Sklar, P; Zhou, Y	1
Kaplun, O; Psevdos, G	1
Conway-Washington, C; Dinh, C; Fountain, J; Haaland, RE; Hall, L; Holder, A; Kelley, CF; Livermont, T; Lupo, LD; Martin, A	1
Burgi, A; Letendre, SL; Little, SJ; Ma, Q; Morse, GD; Ocque, AJ; Sanders, C	1
Castagna, A; Gianotti, N	1
Das, M; Haubrich, R; Maggiolo, F; Mateo-Garcia, MG; McNicholl, I; Molina, JM; Ong, E; Piontkowsky, D; Pulido, F; Raffi, F; Rizzardini, G; Shao, Y	1
Hollenbeck, BL; Kishore, S; Lee, MSL; Padival, S	1
Ajana, F; Bani-Sadr, F; Bouvet, E; Cotte, L; Galempoix, JM; Gantner, P; Hessamfar, M; Hustache-Mathieu, L; Lebrette, MG; Muret, P; Pellissier, G; Piroth, L; Rey, D; Rouveix, E; Simon, A; Souala, MF; Truchetet, F; Valin, N	1
Chuang, YC; Hung, CC; Kuo, PH; Liu, WC; Sun, HY; Wu, PY	1
Amador, C; de Zárraga, MA; Díez Martínez, M; Górgolas, M; Jarrín, I; Moreno, C; Navarro, M; Pérez-Elías, MJ; Pérez-Martínez, L; Ruiz-Algueró, M; Suárez-García, I; Viciana, P	1
Cong, ME; Dinh, C; García-Lerma, JG; Haaland, R; Heneine, W; Holder, A; Johnson, R; Kelley, CF; Kelley, K; Khalil, G; Massud, I; Mills, P; Pan, Y; Ruone, S; Sanchez, T; Zlotorzynska, M	1
Chang, SF; Chang, SY; Chen, GJ; Cheng, CY; Chuang, YC; Hsieh, MH; Huang, SH; Hung, CC; Lee, CH; Lee, YC; Lee, YL; Su, LS; Sun, HY; Tang, HJ; Tsai, HC	1
DeMarais, P; Max, B	1
Cheng, CY; Cheng, SH; Ho, MW; Huang, SH; Huang, YS; Hung, CC; Lee, CH; Lee, YT; Lin, SP; Liou, BH; Liu, CE; Lu, PL; Sun, HY; Tang, HJ; Tsai, HC; Yang, CJ	1
Ma, R; Tong, ZW; Xu, B; Zhang, Q; Zhang, YS; Zhao, CS; Zhao, RG	1
Castagna, A; Esser, S; Haubrich, R; Llibre, JM; Margot, N; McNicholl, IR; Molina, JM; Perez-Valero, I; Piontkowsky, D; Pulido, F; Shao, Y; Temme, L	1
Gao, LY; Hu, Y; Huang, XJ; Ma, P; Wu, H; Wu, Y; Xia, H; Yan, ZF	1
Aydin, OA; Bilge, B; Bolukcu, S; Dokmetas, I; Gumuser, F; Gunduz, A; Karaosmanoglu, HK; Mete, B; Tabak, F; Yildiz, DS	1
Cao, T; He, Y; Jia, X; Ju, B; Liu, J; Liu, X; Peng, Q; Rao, M; Song, Y; Sun, L; Wang, H; Wang, S; Xu, L; Zhang, H; Zhang, L; Zhang, Q; Zhao, F; Zhou, J; Zhou, Y	1
Abdul Massih, S; Andrade, A; Beselman, S; Breakey, J; Fuchs, EJ; Hendrix, CW; Marzinke, MA; McNicholl, I	1
Agrahari, V; Clark, MR; Dinh, C; Doncel, GF; García-Lerma, JG; Heneine, W; Holder, A; Makarova, N; Mendoza, M; Mitchell, J; Pan, Y; Peet, MM; Singletary, T; Smith, JM	1
Agrahari, V; Clark, MR; Dinh, C; Dobard, CW; Doncel, GF; García-Lerma, JG; Gupta, P; Heneine, W; Holder, A; Jonnalagadda, S; Khalil, G; McCormick, TJ; Mitchell, J; Nishiura, K; Pan, Y; Peet, MM; Singh, ON	1
Fan, L; Gao, L; Hu, Y; Huang, R; Li, L; Ma, P; Qiu, C; Wu, Y; Yu, A; Zhang, D	1
Bouldouyre, MA; Brun, A; Caraux-Paz, P; Chabrol, A; De Castro, N; Delaugerre, C; Froguel, E; Garrait, V; Hamet, G; Mechaï, F; Molina, JM; Rozenbaum, W; Sellier, P; Troisvallets, D	1
Anderson, PL; Bushman, LR; Clark, M; Doncel, GF; Fang, X; Hanif, H; Ouattara, LA; Singh, O; Thurman, AR; Yousefieh, N	1
Daharwal, SJ; Singh, VD; Singh, VK	1
Chiarabini, T; Devred, I; Kayembe, K; Lacombe, K; Lambert-Niclot, S; Meyohas, MC; Rougier, H; Shinga, BW; Valin, N	1

Reviews

6 review(s) available for tenofovir and jtk-303

Article	Year
Combinational therapies for HIV: a focus on EVG/COBI/FTC/TDF. Expert opinion on pharmacotherapy, 2012, Volume: 13, Issue:13 Topics: Adenine; Anti-HIV Agents; Carbamates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cobicistat; Deoxycytidine; Drug Combinations; Drug Resistance, Multiple, Viral; Emtricitabine; HIV Infections; Humans; Organophosphonates; Quinolones; Tenofovir; Thiazoles	2012
Single-tablet regimens in HIV: does it really make a difference? Current medical research and opinion, 2014, Volume: 30, Issue:1 Topics: Adenine; Anti-HIV Agents; Carbamates; Cobicistat; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Emtricitabine; HIV Infections; HIV-1; Humans; Nitriles; Organophosphonates; Pyrimidines; Quinolones; Reverse Transcriptase Inhibitors; Rilpivirine; Tablets; Tenofovir; Thiazoles	2014
Elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide for the treatment of HIV in adults. Expert opinion on pharmacotherapy, 2016, Volume: 17, Issue:3 Topics: Anti-HIV Agents; Bone Density; Clinical Trials as Topic; Cobicistat; Drug Combinations; Drug Resistance, Viral; Emtricitabine; HIV Infections; Humans; Quinolones; Tablets; Tenofovir	2016
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection. Drugs, 2016, Volume: 76, Issue:9 Topics: Adenine; Adolescent; Adult; Alanine; Anti-HIV Agents; Clinical Trials, Phase III as Topic; Cobicistat; Drug Combinations; Emtricitabine; HIV Infections; HIV-1; Humans; Quinolones; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Tenofovir	2016
Renal effects of novel antiretroviral drugs. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2017, 03-01, Volume: 32, Issue:3 Topics: Adenine; Alanine; Anti-HIV Agents; Atazanavir Sulfate; Cobicistat; Creatinine; Disease Progression; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Oxazines; Piperazines; Proteinuria; Pyridones; Quinolones; Raltegravir Potassium; Renal Insufficiency, Chronic; Tenofovir	2017
An evaluation of elvitegravir plus cobicistat plus tenofovir alafenamide plus emtricitabine as a single-tablet regimen for the treatment of HIV in children and adolescents. Expert opinion on pharmacotherapy, 2019, Volume: 20, Issue:3 Topics: Adenine; Adolescent; Alanine; Anti-HIV Agents; Child; Cobicistat; Emtricitabine; HIV Infections; Humans; Quinolones; Tablets; Tenofovir; United States; United States Food and Drug Administration	2019

Trials

36 trial(s) available for tenofovir and jtk-303

Article	Year
Pharmacokinetics of emtricitabine, tenofovir, and GS-9137 following coadministration of emtricitabine/tenofovir disoproxil fumarate and ritonavir-boosted GS-9137. Journal of acquired immune deficiency syndromes (1999), 2007, Jul-01, Volume: 45, Issue:3 Topics: Adenine; Administration, Oral; Adolescent; Adult; Antiviral Agents; Cross-Over Studies; Deoxycytidine; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Emtricitabine; Female; Humans; Male; Middle Aged; Organophosphonates; Quinolones; Ritonavir; Tenofovir	2007
Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dose combination regimen for the treatment of HIV. Journal of acquired immune deficiency syndromes (1999), 2010, Volume: 55, Issue:3 Topics: Adenine; Administration, Oral; Adult; Anti-HIV Agents; Biological Availability; Deoxycytidine; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV Integrase; HIV Integrase Inhibitors; Humans; Male; Organophosphonates; Plasma; Quinolones; Tablets; Tenofovir	2010
Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection. AIDS (London, England), 2011, Mar-27, Volume: 25, Issue:6 Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; CD4 Lymphocyte Count; Cobicistat; Cyclopropanes; Deoxycytidine; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Organophosphonates; Patient Compliance; Patient Selection; Quinolones; Tenofovir; Thiazoles; Treatment Outcome	2011
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double- Lancet (London, England), 2012, Jun-30, Volume: 379, Issue:9835 Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Cobicistat; Deoxycytidine; Double-Blind Method; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Quinolones; Ritonavir; Tenofovir; Thiazoles	2012
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet (London, England), 2012, Jun-30, Volume: 379, Issue:9835 Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Cobicistat; Cyclopropanes; Deoxycytidine; Double-Blind Method; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Quinolones; Tenofovir; Thiazoles	2012
A randomized, double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 results Journal of acquired immune deficiency syndromes (1999), 2013, Apr-15, Volume: 62, Issue:5 Topics: Adenine; Adult; Alanine Transaminase; Anti-HIV Agents; Aspartate Aminotransferases; Atazanavir Sulfate; Bilirubin; Bone Density; Carbamates; Cobicistat; Confidence Intervals; Creatinine; Deoxycytidine; Double-Blind Method; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Oligopeptides; Organophosphonates; Pyridines; Quinolones; Ritonavir; RNA, Viral; Tenofovir; Thiazoles; Triglycerides	2013
Effects of a protein-rich drink or a standard meal on the pharmacokinetics of elvitegravir, cobicistat, emtricitabine and tenofovir in healthy Japanese male subjects: a randomized, three-way crossover study. Journal of clinical pharmacology, 2014, Volume: 54, Issue:6 Topics: Adenine; Adult; Anti-HIV Agents; Asian People; Beverages; Carbamates; Cobicistat; Cross-Over Studies; Deoxycytidine; Dietary Proteins; Drug Combinations; Emtricitabine; Food-Drug Interactions; Humans; Male; Middle Aged; Organophosphonates; Quinolones; Tenofovir; Thiazoles; Young Adult	2014
Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week r The Lancet. Infectious diseases, 2014, Volume: 14, Issue:7 Topics: Adenine; Adult; Anti-HIV Agents; Carbamates; Cobicistat; Deoxycytidine; Emtricitabine; Female; HIV; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Quinolones; Reverse Transcriptase Inhibitors; Tenofovir; Thiazoles; Viral Load	2014
Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results o The Lancet. Infectious diseases, 2014, Volume: 14, Issue:7 Topics: Adenine; Adult; Anti-HIV Agents; Carbamates; Cobicistat; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Protease Inhibitors; Quinolones; Ritonavir; Tenofovir; Thiazoles; Viral Load	2014
Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive patients. Antiviral therapy, 2015, Volume: 20, Issue:3 Topics: Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cobicistat; Cyclopropanes; Drug Resistance, Viral; Emtricitabine; Female; Genotype; HIV Infections; HIV-1; Humans; Male; Microbial Sensitivity Tests; Mutation; Quinolones; Tenofovir; Time Factors; Treatment Outcome; Viral Load	2015
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet (London, England), 2015, Jun-27, Volume: 385, Issue:9987 Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Arthralgia; Bone Density; Carbamates; CD4 Lymphocyte Count; Cobicistat; Deoxycytidine; Double-Blind Method; Drug Combinations; Emtricitabine; Female; Headache; HIV Infections; Humans; Kidney; Male; Nausea; Organophosphonates; Quinolones; Respiration Disorders; Sleep Initiation and Maintenance Disorders; Tenofovir; Thiazoles; Treatment Outcome; Viral Load	2015
Patient-Reported Symptoms Over 48 Weeks in a Randomized, Open-Label, Phase IIIb Non-Inferiority Trial of Adults with HIV Switching to Co-Formulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF versus Continuation of Non-Nucleoside Reverse Tra The patient, 2015, Volume: 8, Issue:4 Topics: Adult; Anti-HIV Agents; Cobicistat; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Male; Middle Aged; Patient Outcome Assessment; Quality of Life; Quinolones; Tenofovir	2015
Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study. Journal of acquired immune deficiency syndromes (1999), 2016, Apr-15, Volume: 71, Issue:5 Topics: Adult; Albuminuria; Bone Density; Cobicistat; Drug Substitution; Drug Therapy, Combination; Emtricitabine; Female; Glomerular Filtration Rate; HIV Infections; Humans; Male; Middle Aged; Proteinuria; Quinolones; Renal Insufficiency; Tenofovir	2016
Brief Report: A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 Results. Journal of acquired immune deficiency syndromes (1999), 2016, May-01, Volume: 72, Issue:1 Topics: Adenine; Alanine; Albuminuria; Anti-HIV Agents; Bone Density; CD4 Lymphocyte Count; Cobicistat; Double-Blind Method; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Proteinuria; Quinolones; RNA, Viral; Tenofovir	2016
Rare emergence of drug resistance in HIV-1 treatment-naïve patients after 48 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide. HIV clinical trials, 2016, Volume: 17, Issue:2 Topics: Adenine; Adult; Alanine; Anti-HIV Agents; CD4 Lymphocyte Count; Cobicistat; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Quinolones; Tenofovir; Young Adult	2016
Neither boosted elvitegravir nor darunavir with emtricitabine/tenofovir disoproxil fumarate increase insulin resistance in healthy volunteers: results from the STRIBILD-IR study. Antiviral therapy, 2016, Volume: 21, Issue:7 Topics: Adult; Darunavir; Emtricitabine; Healthy Volunteers; Humans; Insulin Resistance; Prospective Studies; Quinolones; Tenofovir; Triglycerides	2016
Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B-Coinfected Adults. Journal of acquired immune deficiency syndromes (1999), 2016, 11-01, Volume: 73, Issue:3 Topics: Adenine; Alanine; Anti-HIV Agents; Cobicistat; Coinfection; Drug Combinations; Drug Substitution; Emtricitabine; Female; Hepatitis B; HIV Infections; Humans; Male; Middle Aged; Quinolones; Tenofovir; Treatment Outcome	2016
An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy. PloS one, 2016, Volume: 11, Issue:5 Topics: Adult; Algorithms; Anti-HIV Agents; Cobicistat; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Male; Oxazines; Patient Safety; Piperazines; Pyridones; Quinolones; Risk; Tenofovir	2016
Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study. The lancet. HIV, 2016, Volume: 3, Issue:9 Topics: Adult; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Cobicistat; Double-Blind Method; Emtricitabine; Female; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; Humans; International Cooperation; Quinolones; Ritonavir; RNA, Viral; Tenofovir; Viral Load	2016
Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial. The lancet. HIV, 2016, Volume: 3, Issue:12 Topics: Adenine; Adolescent; Alanine; Anti-HIV Agents; Area Under Curve; CD4 Lymphocyte Count; Child; Cobicistat; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lost to Follow-Up; Male; Quinolones; RNA, Viral; South Africa; Tablets; Tenofovir; Thailand; Uganda; United States; Viral Load	2016
Switch as maintenance to elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate: week 48 results in a clinical cohort. The Journal of antimicrobial chemotherapy, 2017, 06-01, Volume: 72, Issue:6 Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cobicistat; Cohort Studies; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Maintenance Chemotherapy; Male; Middle Aged; Polymerase Chain Reaction; Quinolones; RNA, Viral; Tablets; Tenofovir; Viral Load; Viremia	2017
Brief Report: Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: Week 144 Results. Journal of acquired immune deficiency syndromes (1999), 2017, 06-01, Volume: 75, Issue:2 Topics: Adenine; Alanine; Anti-HIV Agents; Bone Density; CD4 Lymphocyte Count; Cobicistat; Double-Blind Method; Emtricitabine; HIV Infections; Humans; Middle Aged; Quinolones; Tenofovir; Treatment Outcome; United States	2017
Effects of a Nutritional Protein-Rich Drink on the Pharmacokinetics of Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide, and Tenofovir Compared With a Standard Meal in Healthy Japanese Male Subjects. Clinical pharmacology in drug development, 2018, Volume: 7, Issue:2 Topics: Adenine; Administration, Oral; Adult; Alanine; Anti-HIV Agents; Asian People; Breakfast; Cobicistat; Cross-Over Studies; Dietary Proteins; Dietary Supplements; Emtricitabine; Fasting; Food-Drug Interactions; Healthy Volunteers; Humans; Male; Quinolones; Tenofovir	2018
Switching to the single-tablet regimen of elvitegravir, cobicistat, emtricitabine, and tenofovir DF from non-nucleoside reverse transcriptase inhibitor plus coformulated emtricitabine and tenofovir DF regimens: Week 96 results of STRATEGY-NNRTI. HIV clinical trials, 2017, Volume: 18, Issue:4 Topics: Adult; Antiretroviral Therapy, Highly Active; Cobicistat; Drug Combinations; Drug Substitution; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Patient Reported Outcome Measures; Quinolones; Tablets; Tenofovir; Time Factors; Treatment Outcome	2017
Week 48 resistance analysis of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF versus Atazanavir + Ritonavir + Emtricitabine/Tenofovir DF in HIV-1 infected women (WAVES study GS-US-236-0128). HIV clinical trials, 2017, Volume: 18, Issue:4 Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cobicistat; Drug Resistance, Viral; Emtricitabine; Female; Genotype; HIV Infections; HIV-1; Humans; Microbial Sensitivity Tests; Mutation; Quinolones; Sequence Analysis, DNA; Tenofovir; Time Factors; Treatment Failure; Treatment Outcome; Viral Load	2017
Tenofovir disoproxil fumarate/emtricitabine plus ritonavir-boosted lopinavir or cobicistat-boosted elvitegravir as a single-tablet regimen for HIV post-exposure prophylaxis. The Journal of antimicrobial chemotherapy, 2017, 10-01, Volume: 72, Issue:10 Topics: Adult; Anti-HIV Agents; Cobicistat; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Medication Adherence; Post-Exposure Prophylaxis; Prospective Studies; Quinolones; Reverse Transcriptase Inhibitors; Ritonavir; Tablets; Tenofovir	2017
HIV treatment simplification to elvitegravir/cobicistat/emtricitabine/tenofovir disproxil fumarate (E/C/F/TDF) plus darunavir: a pharmacokinetic study. AIDS research and therapy, 2017, Nov-02, Volume: 14, Issue:1 Topics: Adult; Aged; Anti-HIV Agents; Cobicistat; Darunavir; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Integrase Inhibitors; Male; Middle Aged; Protease Inhibitors; Quinolones; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Viral Load	2017
Superior Efficacy and Improved Renal and Bone Safety After Switching from a Tenofovir Disoproxil Fumarate- to a Tenofovir Alafenamide-Based Regimen Through 96 Weeks of Treatment. AIDS research and human retroviruses, 2018, Volume: 34, Issue:4 Topics: Adenine; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Bone Density; Cobicistat; Drug Combinations; Drug Substitution; Emtricitabine; HIV Infections; HIV-1; Humans; Kidney; Quinolones; RNA, Viral; Tenofovir; Treatment Outcome	2018
Brief Report: Efficacy and Safety of Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide (E/C/F/TAF) in Virologically Suppressed Women. Journal of acquired immune deficiency syndromes (1999), 2018, 06-01, Volume: 78, Issue:2 Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cobicistat; Double-Blind Method; Drug Combinations; Drug Resistance, Viral; Drug-Related Side Effects and Adverse Reactions; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Integrase Inhibitors; Protease Inhibitors; Quinolones; RNA, Viral; Tenofovir	2018
Seminal Tenofovir Concentrations, Viral Suppression, and Semen Quality With Tenofovir Alafenamide, Compared With Tenofovir Disoproxil Fumarate (Spanish HIV/AIDS Research Network, PreEC/RIS 40). Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2019, 09-27, Volume: 69, Issue:8 Topics: Adenine; Adult; Alanine; Anti-Retroviral Agents; Cobicistat; Emtricitabine; HIV Infections; HIV-1; Humans; Male; Middle Aged; Prospective Studies; Quinolones; RNA, Viral; Semen; Semen Analysis; Tenofovir	2019
Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial. Journal of acquired immune deficiency syndromes (1999), 2019, 08-01, Volume: 81, Issue:4 Topics: Adult; Aged; Anti-Retroviral Agents; Equivalence Trials as Topic; Female; HIV-1; Humans; Lamivudine; Male; Middle Aged; Protease Inhibitors; Pyridones; Quinolones; Ritonavir; Tenofovir; Treatment Outcome; Triazoles; Young Adult	2019
Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regimen: a m The lancet. HIV, 2019, Volume: 6, Issue:10 Topics: Adenine; Aged; Aged, 80 and over; Alanine; Anti-HIV Agents; Bone Density; Cobicistat; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Quinolones; Tablets; Tenofovir	2019
Elvitegravir-Cobicistat-Emtricitabine-Tenofovir Alafenamide Single-tablet Regimen for Human Immunodeficiency Virus Postexposure Prophylaxis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 02-14, Volume: 70, Issue:5 Topics: Adenine; Alanine; Anti-HIV Agents; Cobicistat; Drug Combinations; Emtricitabine; HIV Infections; HIV-1; Humans; Quinolones; Tablets; Tenofovir	2020
EVG/COBI/FTC/TAF Bioequivalence Comparing Whole Tablets with Tablets Dissolved in Tap Water. AIDS research and human retroviruses, 2023, Volume: 39, Issue:1 Topics: Adenine; Adult; Anti-HIV Agents; Cobicistat; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Male; Tablets; Tenofovir; Therapeutic Equivalency	2023
Single dose topical inserts containing tenofovir alafenamide fumarate and elvitegravir provide pre- and post-exposure protection against vaginal SHIV infection in macaques. EBioMedicine, 2022, Volume: 86 Topics: Adenine; Animals; Anti-HIV Agents; Female; Fumarates; HIV Infections; Macaca; Pre-Exposure Prophylaxis; Tenofovir	2022
A phase I study to assess safety, pharmacokinetics, and pharmacodynamics of a vaginal insert containing tenofovir alafenamide and elvitegravir. Frontiers in cellular and infection microbiology, 2023, Volume: 13 Topics: Alanine; Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Tenofovir	2023

Other Studies

53 other study(ies) available for tenofovir and jtk-303

Article	Year
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology. Disease models & mechanisms, 2023, 03-01, Volume: 16, Issue:3 Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries	2023
Identification and characterization of persistent intracellular human immunodeficiency virus type 1 integrase strand transfer inhibitor activity. Antimicrobial agents and chemotherapy, 2011, Volume: 55, Issue:1 Topics: Adenine; Anti-HIV Agents; Cell Line; HeLa Cells; HIV-1; Humans; Integrase Inhibitors; Organophosphonates; Pyrrolidinones; Quinolones; Raltegravir Potassium; Tenofovir; Zidovudine	2011
[A single tablet against HIV: new combination preparation improves therapy]. Deutsche medizinische Wochenschrift (1946), 2012, Volume: 137, Issue:34-35 Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Carbamates; CD4 Lymphocyte Count; Clinical Trials, Phase III as Topic; Cobicistat; Cyclopropanes; Deoxycytidine; Double-Blind Method; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Glomerular Filtration Rate; HIV Infections; Humans; Oligopeptides; Organophosphonates; Pyridines; Quinolones; Randomized Controlled Trials as Topic; Ritonavir; Tenofovir; Thiazoles; Viral Load	2012
FDA approves new 4-drug once-a-day HIV treatment. AIDS policy & law, 2012, Volume: 27, Issue:11 Topics: Adenine; Carbamates; Cobicistat; Deoxycytidine; Drug Administration Schedule; Drug Approval; Drug Combinations; Emtricitabine; HIV Infections; Humans; Organophosphonates; Quinolones; Tenofovir; Thiazoles; United States; United States Food and Drug Administration	2012
A 4-drug combination (Stribild) for HIV. The Medical letter on drugs and therapeutics, 2012, Nov-26, Volume: 54, Issue:1404 Topics: Adenine; Anti-HIV Agents; Carbamates; Clinical Trials as Topic; Cobicistat; Deoxycytidine; Double-Blind Method; Drug Approval; Drug Combinations; Drug Interactions; Drug Resistance, Multiple, Viral; Emtricitabine; HIV; HIV Infections; Humans; Organophosphonates; Quinolones; Randomized Controlled Trials as Topic; Tenofovir; Thiazoles; United States; United States Food and Drug Administration	2012
HIV-2 antiviral potency and selection of drug resistance mutations by the integrase strand transfer inhibitor elvitegravir and NRTIs emtricitabine and tenofovir in vitro. Journal of acquired immune deficiency syndromes (1999), 2013, Apr-01, Volume: 62, Issue:4 Topics: Adenine; Base Sequence; Deoxycytidine; DNA Primers; Drug Resistance, Viral; Emtricitabine; HEK293 Cells; HIV Integrase Inhibitors; HIV-2; Humans; In Vitro Techniques; Mutation; Organophosphonates; Polymerase Chain Reaction; Quinolones; Reverse Transcriptase Inhibitors; Tenofovir	2013
Drug updates and approvals: 2012 in review. The Nurse practitioner, 2013, Feb-10, Volume: 38, Issue:2 Topics: Acetanilides; Adenine; Antibodies, Monoclonal, Humanized; Benzazepines; Carbamates; Cobicistat; Deoxycytidine; Drug Approval; Drug Combinations; Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Emtricitabine; Fatty Alcohols; Humans; Mifepristone; Nicotinic Acids; Nurse Practitioners; Organophosphonates; Phosphatidylglycerols; Prednisone; Proteins; Pyrimidines; Quinolones; Ranibizumab; Tenofovir; Thiazoles; United States; United States Food and Drug Administration	2013
[ First integrase inhibitor based single tablet regimen]. MMW Fortschritte der Medizin, 2013, Jun-13, Volume: 155 Suppl 1 Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Carbamates; Cobicistat; Deoxycytidine; Drug Approval; Drug Combinations; Emtricitabine; HIV Infections; HIV Integrase Inhibitors; Humans; Organophosphonates; Quinolones; Tenofovir; Thiazoles; Treatment Outcome	2013
Validation of a fast method for quantitative analysis of elvitegravir, raltegravir, maraviroc, etravirine, tenofovir, boceprevir and 10 other antiretroviral agents in human plasma samples with a new UPLC-MS/MS technology. Journal of pharmaceutical and biomedical analysis, 2013, Volume: 86 Topics: Adenine; Anti-Retroviral Agents; Chromatography, High Pressure Liquid; Cyclohexanes; Humans; Maraviroc; Mass Spectrometry; Nitriles; Organophosphonates; Proline; Pyridazines; Pyrimidines; Pyrrolidinones; Quinolones; Raltegravir Potassium; Tandem Mass Spectrometry; Tenofovir; Time Factors; Triazoles	2013
Cobicistat + elvitegravir + emtricitabine + tenofovir. Two new drugs, but no progress. Prescrire international, 2013, Volume: 22, Issue:142 Topics: Acquired Immunodeficiency Syndrome; Adenine; Anti-HIV Agents; Carbamates; Cobicistat; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV-1; Humans; Organophosphonates; Quinolones; Tenofovir; Thiazoles	2013
Single-tablet, once-daily treatment regimens for HIV. The Lancet. Infectious diseases, 2014, Volume: 14, Issue:4 Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Cobicistat; Cyclopropanes; Cytochrome P-450 CYP3A Inhibitors; Deoxycytidine; Drug Combinations; Emtricitabine; HIV Infections; HIV Integrase Inhibitors; HIV Reverse Transcriptase; Humans; Nitriles; Organophosphonates; Pyrimidines; Quinolones; Reverse Transcriptase Inhibitors; Rilpivirine; Tenofovir; Thiazoles	2014
Sustained virological response after taking crushed elvitegravir-cobicistat-emtricitabine-tenofovir tablets. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2014, May-15, Volume: 71, Issue:10 Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Carbamates; Cobicistat; Deoxycytidine; Emtricitabine; Female; HIV; HIV Infections; Humans; Organophosphonates; Powders; Quinolones; Tablets; Tenofovir; Thiazoles; Viral Load	2014
Switching STRATEGIES in HIV treatment. The Lancet. Infectious diseases, 2014, Volume: 14, Issue:7 Topics: Adenine; Anti-HIV Agents; Carbamates; Cobicistat; Deoxycytidine; Emtricitabine; Female; HIV; HIV Infections; Humans; Male; Organophosphonates; Protease Inhibitors; Quinolones; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Thiazoles	2014
The combined anti-HIV-1 activities of emtricitabine and tenofovir plus the integrase inhibitor elvitegravir or raltegravir show high levels of synergy in vitro. Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:10 Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Synergism; Emtricitabine; Integrase Inhibitors; Organophosphonates; Pyrrolidinones; Quinolones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Tenofovir	2014
Elvitegravir/cobicistat/emtricitabine/tenofovir DF in HIV-infected patients with mild-to-moderate renal impairment. Journal of acquired immune deficiency syndromes (1999), 2015, Mar-01, Volume: 68, Issue:3 Topics: Adenine; Adult; Anti-HIV Agents; Carbamates; Cobicistat; Cohort Studies; Deoxycytidine; Emtricitabine; Female; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Quinolones; Renal Insufficiency; Tenofovir; Thiazoles; Treatment Outcome	2015
Tenofovir alafenamide for HIV infection: is less more? Lancet (London, England), 2015, Jun-27, Volume: 385, Issue:9987 Topics: Adenine; Alanine; Anti-HIV Agents; Carbamates; Cobicistat; Deoxycytidine; Emtricitabine; Female; HIV Infections; Humans; Male; Organophosphonates; Quinolones; Tenofovir; Thiazoles	2015
Drug Susceptibility and Viral Fitness of HIV-1 with Integrase Strand Transfer Inhibitor Resistance Substitution Q148R or N155H in Combination with Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Resistance Substitutions. Antimicrobial agents and chemotherapy, 2016, Volume: 60, Issue:2 Topics: Anti-HIV Agents; Cobicistat; Drug Resistance, Multiple, Viral; Emtricitabine; HIV Integrase; HIV Integrase Inhibitors; HIV-1; Humans; Quinolones; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Tenofovir; Virus Replication	2016
Genvoya--a new 4-drug combination for HIV. The Medical letter on drugs and therapeutics, 2016, Feb-15, Volume: 58, Issue:1488 Topics: Cobicistat; Drug Combinations; Drug Interactions; Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Emtricitabine; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Quinolones; Randomized Controlled Trials as Topic; Tenofovir; Treatment Outcome	2016
Elvitegravir/Cobicistat/Tenofovir/Emtricitabine Penetration in the Cerebrospinal Fluid of Three HIV-Positive Patients. AIDS research and human retroviruses, 2016, Volume: 32, Issue:5 Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cobicistat; Emtricitabine; Female; HIV Infections; Humans; Male; Middle Aged; Quinolones; Tenofovir	2016
Simultaneous quantification of tenofovir, emtricitabine, rilpivirine, elvitegravir and dolutegravir in mouse biological matrices by LC-MS/MS and its application to a pharmacokinetic study. Journal of pharmaceutical and biomedical analysis, 2016, Sep-10, Volume: 129 Topics: Animals; Anti-Retroviral Agents; Chromatography, Liquid; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Mice; Oxazines; Piperazines; Pyridones; Quinolones; Rilpivirine; Solid Phase Extraction; Tandem Mass Spectrometry; Tenofovir	2016
Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection. The Journal of antimicrobial chemotherapy, 2017, Volume: 72, Issue:2 Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cobicistat; Emtricitabine; HIV; HIV Infections; Humans; Male; Middle Aged; Quinolones; Retrospective Studies; Tenofovir; Treatment Outcome; Viral Load	2017
Tenofovir alafenamide, emtricitabine, elvitegravir, and cobicistat combination therapy for the treatment of HIV. Expert review of anti-infective therapy, 2017, Volume: 15, Issue:3 Topics: Anti-HIV Agents; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cobicistat; Drug Combinations; Drug Interactions; Emtricitabine; HIV Infections; Humans; Quinolones; Tenofovir	2017
Tenofovir alafenamide and elvitegravir loaded nanoparticles for long-acting prevention of HIV-1 vaginal transmission. AIDS (London, England), 2017, 02-20, Volume: 31, Issue:4 Topics: Adenine; Alanine; Animals; Delayed-Action Preparations; Disease Transmission, Infectious; Female; HIV Infections; Injections, Subcutaneous; Mice; Mice, SCID; Nanoparticles; Plasma; Quinolones; Tenofovir; Treatment Outcome; Vagina; Viral Load	2017
Comment on: Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection. The Journal of antimicrobial chemotherapy, 2017, 05-01, Volume: 72, Issue:5 Topics: Adenine; Anti-HIV Agents; Cobicistat; Deoxycytidine; Emtricitabine; HIV Infections; Humans; Organophosphonates; Quinolones; Tenofovir	2017
Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection-authors' response. The Journal of antimicrobial chemotherapy, 2017, 05-01, Volume: 72, Issue:5 Topics: Adenine; Anti-HIV Agents; Cobicistat; Deoxycytidine; Emtricitabine; HIV Infections; Humans; Organophosphonates; Quinolones; Tenofovir	2017
High decay of blood HIV reservoir when tenofovir/emtricitabine/elvitegravir/cobicistat is initiated during the acute primary HIV infection. The Journal of antimicrobial chemotherapy, 2017, 09-01, Volume: 72, Issue:9 Topics: Adult; Anti-HIV Agents; Blood; Cobicistat; Emtricitabine; HIV Infections; HIV-1; Humans; Male; Middle Aged; Quinolones; Secondary Prevention; Tenofovir; Treatment Outcome; Viral Load	2017
Safety and tolerability of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil fumarate in a real life setting: Data from surveillance cohort long-term toxicity antiretrovirals/antivirals (SCOLTA) project. PloS one, 2017, Volume: 12, Issue:6 Topics: Adult; Anti-HIV Agents; Cobicistat; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Maximum Tolerated Dose; Middle Aged; Quinolones; Safety; Tenofovir	2017
Effect of Cobicistat on Tenofovir Disoproxil Fumarate (TDF): What Is True for TAF May Also Be True for TDF. Journal of acquired immune deficiency syndromes (1999), 2018, 01-01, Volume: 77, Issue:1 Topics: Adenine; Adult; Aged; Alanine; Anti-HIV Agents; Cobicistat; Drug Combinations; Drug Interactions; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Oxazines; Piperazines; Proportional Hazards Models; Pyridones; Quinolones; Raltegravir Potassium; Ritonavir; Tenofovir; Treatment Outcome	2018
Human Immunodeficiency Virus Type 1 Drug Resistance Mutations Update. The Journal of infectious diseases, 2017, 12-01, Volume: 216, Issue:suppl_9 Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; HIV-1; Humans; Lopinavir; Mutation; Oxazines; Piperazines; Pyridones; Quinolones; Raltegravir Potassium; Rilpivirine; Tenofovir	2017
Overdose of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in an HIV-1-infected subject with attempted suicide. Infection, 2019, Volume: 47, Issue:1 Topics: Adenine; Alanine; Anti-HIV Agents; Cobicistat; Drug Combinations; Drug Overdose; Emtricitabine; HIV Infections; Humans; Male; Middle Aged; Quinolones; Renal Insufficiency; Suicide, Attempted; Tenofovir	2019
Efficacy and safety of switching to dolutegravir plus emtricitabine/tenofovir disoproxil fumarate (TDF) or elvitegravir/cobicistat/emtricitabine/TDF in virologically suppressed HIV-infected patients in clinical practice: results from a multicentre, observ HIV medicine, 2019, Volume: 20, Issue:2 Topics: Adult; Cobicistat; Drug Therapy, Combination; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Quinolones; Retrospective Studies; RNA, Viral; Tenofovir; Viral Load	2019
Abnormal elevation of international normalized ratio in a patient during the coadministration of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide and warfarin: a case report. AIDS (London, England), 2019, 02-01, Volume: 33, Issue:2 Topics: Adenine; Alanine; Cobicistat; Emtricitabine; HIV Infections; Humans; International Normalized Ratio; Quinolones; Tenofovir; Warfarin	2019
Sustained HIV virologic suppression with crushed combination tablets containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2019, 08-01, Volume: 76, Issue:16 Topics: Adenine; Alanine; Anti-HIV Agents; Cobicistat; Drug Therapy, Combination; Emtricitabine; Enteral Nutrition; Gastrostomy; HIV Infections; HIV-1; Humans; Male; Middle Aged; Quinolones; Sustained Virologic Response; Tablets; Tenofovir	2019
Brief Report: Urine Emtricitabine and Tenofovir Concentrations Provide Markers of Recent Antiretroviral Drug Exposure Among HIV-Negative Men Who Have Sex With Men. Journal of acquired immune deficiency syndromes (1999), 2019, 11-01, Volume: 82, Issue:3 Topics: Adenine; Administration, Oral; Adolescent; Adult; Alanine; Anti-HIV Agents; Anti-Retroviral Agents; Biomarkers; Cobicistat; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Male; Middle Aged; Quinolones; Sexual and Gender Minorities; Tenofovir; Time Factors; Young Adult	2019
Switching to Tenofovir Alafenamide in Elvitegravir-Based Regimens: Pharmacokinetics and Antiviral Activity in Cerebrospinal Fluid. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 08-14, Volume: 71, Issue:4 Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Emtricitabine; HIV Infections; Humans; Quinolones; Tenofovir	2020
Switching antiretrovirals in older patients. The lancet. HIV, 2019, Volume: 6, Issue:10 Topics: Adenine; Aged; Alanine; Bone Density; Cobicistat; Emtricitabine; HIV Infections; HIV-1; Humans; Middle Aged; Quinolones; Tablets; Tenofovir	2019
Fevers and Night Sweats in a 35-year-old Man With Recent Travel to Southeast Asia. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2019, 10-15, Volume: 69, Issue:9 Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Asia, Southeastern; Cobicistat; Emtricitabine; HIV Infections; Humans; Laos; Male; Quinolones; Sweating; Tenofovir; Thailand; Travel; United States	2019
Weight gain and dyslipidemia among virally suppressed HIV-positive patients switching to co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2020, Volume: 92 Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cobicistat; Dyslipidemias; Emtricitabine; Female; HIV Seropositivity; Humans; Lipids; Male; Middle Aged; Quinolones; Retrospective Studies; Tenofovir; Weight Gain	2020
Effectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir among treatment-experienced patients in clinical practice: a multicentre cohort study. AIDS research and therapy, 2020, 07-20, Volume: 17, Issue:1 Topics: Adult; Anti-HIV Agents; Cobicistat; Darunavir; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Quinolones; Spain; Tenofovir; Treatment Outcome; Viral Load	2020
Single oral dose for HIV pre or post-exposure prophylaxis: user desirability and biological efficacy in macaques. EBioMedicine, 2020, Volume: 58 Topics: Adenine; Administration, Oral; Animals; Cross-Sectional Studies; Drug Combinations; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Macaca; Male; Patient Compliance; Pre-Exposure Prophylaxis; Quinolones; Rectum; Surveys and Questionnaires; Tenofovir	2020
Impact of archived M184V/I mutation on the effectiveness of switch to co-formulated elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide among virally suppressed people living with HIV. The Journal of antimicrobial chemotherapy, 2020, 10-01, Volume: 75, Issue:10 Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Cobicistat; Emtricitabine; HIV Infections; HIV-1; Humans; Mutation; Quinolones; Retrospective Studies; Tenofovir	2020
Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide discontinuation and return to normal weight. International journal of STD & AIDS, 2021, Volume: 32, Issue:1 Topics: Adult; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cobicistat; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Quinolones; Tenofovir; Weight Gain	2021
Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide as Maintenance Treatment in HIV/HBV-Coinfected Patients. Journal of acquired immune deficiency syndromes (1999), 2021, 04-01, Volume: 86, Issue:4 Topics: Adult; Alanine; Anti-HIV Agents; Cobicistat; Cohort Studies; Drug Combinations; Drug Substitution; Emtricitabine; Female; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Male; Middle Aged; Prospective Studies; Quinolones; Taiwan; Tenofovir	2021
Preoperative rapid suppression of viral load by elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide regimen in human immunodeficiency virus-positive fracture patients significantly reduces postoperative complications. Chinese medical journal, 2020, Dec-05, Volume: 133, Issue:23 Topics: Adenine; Alanine; Anti-HIV Agents; Cobicistat; Drug Combinations; Emtricitabine; HIV; HIV Infections; Humans; Postoperative Complications; Quinolones; Tenofovir; Viral Load	2020
Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Adults With HIV and M184V/I Mutation. Journal of acquired immune deficiency syndromes (1999), 2021, 04-01, Volume: 86, Issue:4 Topics: Adult; Aged; Alanine; Anti-HIV Agents; Cobicistat; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Mutation; Quinolones; Tenofovir; Young Adult	2021
Switching from efavirenz to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide reduces central nervous system symptoms in people living with HIV. Chinese medical journal, 2021, Oct-13, Volume: 134, Issue:23 Topics: Adenine; Adult; Alanine; Alkynes; Anti-HIV Agents; Benzoxazines; Central Nervous System; Cobicistat; Cyclopropanes; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Male; Prospective Studies; Quality of Life; Quinolones; Sleep Quality; Tenofovir	2021
Effectiveness and safety of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single-tablet combination among HIV-infected patients in Turkey: results from a real world setting. African health sciences, 2021, Volume: 21, Issue:4 Topics: Adult; Anti-HIV Agents; Cobicistat; Drug Combinations; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Male; Quinolones; Retrospective Studies; Tablets; Tenofovir; Turkey	2021
Higher Risk of Dyslipidemia With Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide than Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate Among Antiretroviral-Naive People Living With HIV in China. Journal of acquired immune deficiency syndromes (1999), 2022, 10-01, Volume: 91, Issue:S1 Topics: Adenine; Alanine; Alkynes; Anti-HIV Agents; Anti-Retroviral Agents; Benzoxazines; Cholesterol, LDL; Cobicistat; Cyclopropanes; Emtricitabine; HIV Infections; HIV-1; Humans; Hypercholesterolemia; Hypertriglyceridemia; Lamivudine; Lipoproteins, HDL; Quinolones; Retrospective Studies; Tenofovir	2022
Pharmacokinetics and efficacy of topical inserts containing tenofovir alafenamide fumarate and elvitegravir administered rectally in macaques. EBioMedicine, 2022, Volume: 86 Topics: Alanine; Animals; Anti-HIV Agents; Female; Fumarates; HIV Infections; Leukocytes, Mononuclear; Macaca; Tenofovir; Tissue Distribution	2022
Advantages of switching to elvitegravir/cobicistat/emtricitabine/tenofovir therapy in virologically-suppressed people living with human immunodeficiency virus/acquired immune deficiency syndrome. Chinese medical journal, 2022, 11-20, Volume: 135, Issue:22 Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Cobicistat; Drug Combinations; Emtricitabine; HIV; HIV Infections; Humans; Tenofovir	2022
Safety and efficacy of switching to elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate in treatment-experienced people with HIV: a multicenter cohort study. AIDS research and therapy, 2023, 01-03, Volume: 20, Issue:1 Topics: Adult; Anti-HIV Agents; Cobicistat; Cohort Studies; Emtricitabine; Female; HIV Infections; Humans; Integrase Inhibitors; Male; RNA; Tenofovir	2023
Utilization of Chemometric-Aided UV Spectrophotometric Methods for Concurrent Assessment of Emtricitabine, Tenofovir Disoproxil Fumarate, Elvitegravir, and Cobicistat in Tablet Formulation. Journal of AOAC International, 2023, Nov-02, Volume: 106, Issue:6 Topics: Adenine; Anti-HIV Agents; Chemometrics; Cobicistat; Drug Combinations; Emtricitabine; HIV Infections; Humans; Tablets; Tenofovir	2023
Prophylaxis by doravirine-lamivudine-tenofovir disoproxil fumarate or elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide after sexual exposure to HIV. BMC infectious diseases, 2023, Sep-04, Volume: 23, Issue:1 Topics: Adult; Anti-HIV Agents; Cobicistat; Drug-Related Side Effects and Adverse Reactions; Emtricitabine; Fumarates; HIV Infections; Humans; Lamivudine; Tenofovir	2023

chemdatabank.com